Trial Profile
A Randomized Phase 3 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6-methylguanine DNA methyltransferase) Glioblastoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 04 Mar 2024
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Registrational; Therapeutic Use
- Acronyms CheckMate 548
- Sponsors Bristol-Myers Squibb
- 26 Feb 2024 Planned End Date changed from 19 Feb 2024 to 30 Apr 2024.
- 18 Aug 2023 Planned End Date changed from 1 Aug 2023 to 19 Feb 2024.
- 02 Nov 2022 Results assessing safety and efficacy of temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma, published in the Neuro-Oncology.